Elevated CD6 expression on B and T cells in SS-affected salivary glands opens the door for itolizumab, an anti-CD6 monoclonal antibody, as an immune activation inhibitor (Alonso et al., 2010; Le Dantec et al., 2013). This evidence concerns the gene CD6 and synovial sarcoma.